34584-69-5

Basic information

• Product Name: 3,6-Dichloro-4,5-dimethylpyridazine
• Synonyms: 3,6-DICHLORO-4,5-DIMETHYLPYRIDAZINE;Pyridazine, 3,6-dichloro-4,5-diMethyl-
• CAS NO: 34584-69-5
• Molecular Formula: C₆H₆Cl₂N₂
• Molecular Weight: 177.03
• Mol File: 34584-69-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 120-121 °C
• Boiling Point: 317.165 °C at 760 mmHg
• Flash Point: 174.99 °C
• Appearance: /
• Density: 1.338 g/cm³
• Vapor Pressure: 0.000728mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.29±0.10(Predicted)
• CAS DataBase Reference: 3,6-Dichloro-4,5-dimethylpyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dichloro-4,5-dimethylpyridazine(34584-69-5)
• EPA Substance Registry System: 3,6-Dichloro-4,5-dimethylpyridazine(34584-69-5)

Safety Data

• Hazardous Substances Data: 34584-69-5(Hazardous Substances Data)

Usage

Description

3,6-Dichloro-4,5-dimethylpyridazine is a heterocyclic organic compound characterized by the presence of a pyridazine ring with two chlorine atoms at the 3rd and 6th positions and two methyl groups at the 4th and 5th positions. 3,6-Dichloro-4,5-dimethylpyridazine is known for its potential applications in various industries, particularly as a pharmaceutical intermediate due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
3,6-Dichloro-4,5-dimethylpyridazine is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its chemical structure allows for further functionalization and modification, making it a versatile building block in the development of new pharmaceutical compounds. 3,6-Dichloro-4,5-dimethylpyridazine's reactivity and stability contribute to its utility in creating a wide range of therapeutic agents.
As a pharmaceutical intermediate, 3,6-Dichloro-4,5-dimethylpyridazine plays a crucial role in the development of new drugs with potential applications in treating various medical conditions. Its unique structure and properties enable chemists to design and synthesize novel compounds with improved pharmacological profiles, including enhanced efficacy, selectivity, and safety profiles. This makes 3,6-Dichloro-4,5-dimethylpyridazine a valuable asset in the ongoing efforts to discover and develop innovative therapeutic solutions to address unmet medical needs.

InChI:InChI=1/C6H6Cl2N2/c1-3-4(2)6(8)10-9-5(3)7/h1-2H3

Upstream product

• 71-43-2 benzene 
• 766-39-2 2,3-Dimethylmaleic anhydride 
• 5754-17-6 6-hydroxy-4,5-dimethylpyridazin-3-one 
• 63751-07-5 1-amino-3,4-dimethyl-pyrrole-2,5-dione 
• 5754-17-6 4,5-dimethyl-1,2-dihydro-pyridazine-3,6-dione 

Downstream Products

• 76593-36-7 3-amino-6-chloro-4,5-dimethylpyridazine 
• 328554-59-2 6-chloro-3-(4-fluoro-phenyl)-2-(4-methanesulfonyl-phenyl)-7,8-dimethyl-imidazo[1,2-b]pyridazine 
• 1204978-32-4 3-chloro-4,5-dimethyl-6-((R)-3-methyl-piperazin-1-yl)-pyridazine 
• 1204978-49-3 3-Chloro-4,5-dimethyl-6-[(R)-3-methyl-4-(5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-pyridazine 
• 1204977-38-7 (6-chloro-4,5-dimethyl-pyridazin-3-yl)-phenyl-methanone 
• 959841-61-3 5-[(6-chloro-4,5-dimethylpyridazin-3-yl)(cyano)methyl]-2-fluorobenzonitrile 
• 1227064-32-5 N₁-benzyl-N₂-(6-chloro-4,5-dimethylpyridazin-3-yl)ethane-1,2-diamine 
• 1204975-90-5 2-(6-(4-(6-(4-fluorobenzyl)-4,5-dimethylpyridazin-3-yl)piperazin-1-yl)pyridin-3-yl)propan-2-ol 
• 1204978-14-2 3-benzyl-4,5-dimethyl-6-(piperazin-1-yl)pyridazine 
• 1204978-10-8 3-benzyl-4,5-dimethyl-6-((R)-3-methyl-piperazin-1-yl)-pyridazine 
• 1204978-26-6 (S)-3-benzyl-4,5-dimethyl-6-(3-methylpiperazin-1-yl)pyridazine 
• 1204978-29-9 (R)-3-benzyl-6-(3-ethylpiperazin-1-yl)-4,5-dimethylpyridazine 
• 1204975-13-2 methyl 5-(4-(6-benzyl-4,5-dimethylpyridazin-3-yl)piperazin-1-yl)pyrazine-2-carboxylate 
• 1204975-11-0 (R)-4-(6-benzyl-4,5-dimethyl-pyridazin-3-yl)-2-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-carboxylic acid methyl ester 

Relevant articles and documents

-

-

PYRIDAZINE DERIVATIVES AS HEDGEHOG PATHWAY INHIBITORS

This invention relates to novel compounds. The compounds of the invention are hedgehog pathway agonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) agonists. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The i